Medications for Acute Opioid Withdrawal
For moderate to severe acute opioid withdrawal (COWS >8), give buprenorphine 4-8 mg sublingually as the first-line treatment, as it provides superior symptom relief, fewer adverse effects, and better treatment retention compared to all other options. 1
Treatment Algorithm Based on Withdrawal Severity
Step 1: Assess Withdrawal Severity Using COWS Score
Mild withdrawal (COWS <8):
- No buprenorphine indicated initially
- Reassess in 1-2 hours
- Use symptomatic management (see below)
Moderate to severe withdrawal (COWS ≥8):
- Administer buprenorphine 4-8 mg sublingually based on severity
- Reassess after 30-60 minutes
- Target total daily dose of 16 mg for most patients 1
Step 2: Confirm Timing Since Last Opioid Use
This is critical to avoid precipitated withdrawal with buprenorphine:
- Short-acting opioids (heroin, morphine IR): >12 hours since last use
- Extended-release formulations (OxyContin): >24 hours since last use
- Methadone maintenance patients: >72 hours since last use (consider methadone instead of buprenorphine in these patients) 1
Important caveat: Fentanyl may require >12 hours despite being short-acting due to tissue accumulation 2
Medication Options by Efficacy
First-Line: Buprenorphine (Most Effective)
Buprenorphine is the most effective treatment based on meta-analyses showing it produces less severe withdrawal symptoms, fewer adverse effects, and longer treatment retention compared to clonidine, lofexidine, or methadone 1.
Dosing:
- Initial: 4-8 mg sublingual
- Reassess after 30-60 minutes
- Target 16 mg total on day 1 for most patients
- Can prescribe up to 3 days without X-waiver (now eliminated as of 2023) 1, 2
Critical pitfall: Buprenorphine can precipitate withdrawal if given too soon after full agonist use due to its partial agonist properties displacing full agonists from receptors 3
Second-Line: Methadone (Effective but Restricted)
Methadone is similarly effective to buprenorphine for withdrawal but has significant practical limitations 1. While physicians can administer methadone in the ED/hospital for up to 72 hours without an opioid treatment program, its long duration of action (hours to days) and potential to interfere with ongoing treatment programs make it less commonly used 1.
When to consider methadone:
- Patients on methadone maintenance (>72 hours since last dose)
- Patients who cannot tolerate or fail buprenorphine
- Starting dose: 30-40 mg/day prevents withdrawal in most patients 4
Third-Line: Symptomatic Management with Non-Opioids
When opioid agonist therapy is unavailable, declined, or contraindicated, use combination symptomatic treatment 1:
α2-Adrenergic agonists (most important non-opioid option):
- Clonidine or lofexidine for autonomic symptoms
- Only use in non-hypotensive patients
- These are less effective than buprenorphine but superior to other non-opioid options 5
Adjunctive medications:
- Antiemetics (promethazine) for nausea/vomiting
- Benzodiazepines to reduce catecholamine release, muscle cramps, and anxiety
- Loperamide for diarrhea
- Gabapentin, hydroxyzine, muscle relaxants as additional adjuncts 1, 6
Key Clinical Considerations
Regarding naltrexone: This is NOT appropriate for acute withdrawal as it precipitates severe withdrawal in opioid-dependent patients and requires 7-10 days of abstinence before administration 3
Regarding short-acting full agonist opioids (SAFAOs): Emerging evidence suggests hydromorphone, oxycodone, or fentanyl may be useful adjuncts when methadone/buprenorphine are insufficient, particularly with high-potency fentanyl tolerance, but this remains investigational and carries oversedation risks 7, 8
Harm reduction essentials: Always provide overdose prevention education, prescribe take-home naloxone, and offer hepatitis C/HIV screening regardless of which withdrawal medication is chosen 1
Why Buprenorphine is Superior
The 2020 ACEP guidelines 1 synthesize multiple meta-analyses demonstrating buprenorphine's superiority stems from:
- More complete symptom relief than α2-agonists
- Safer respiratory depression profile than methadone (ceiling effect)
- Ability to initiate medication for opioid use disorder simultaneously
- Better treatment retention and reduced mortality long-term
The evidence is clear: buprenorphine should be the default choice for moderate-severe withdrawal unless specific contraindications exist (too soon after full agonist use, patient on methadone maintenance, or patient preference). 1